Rein Therapeutics Inc. (NASDAQ:RNTX) Receives Consensus Rating of “Hold” from Analysts

Shares of Rein Therapeutics Inc. (NASDAQ:RNTX) have been given an average rating of “Hold” by the four brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $6.00.

Several equities analysts have commented on the company. Maxim Group started coverage on Rein Therapeutics in a report on Monday, July 20th. They issued a “buy” rating and a $4.00 price target for the company. Wall Street Zen upgraded Rein Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Weiss Ratings lowered Rein Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Rein Therapeutics in a research report on Tuesday, August 18th.

Institutional Trading of Rein Therapeutics

Several institutional investors have recently made changes to their positions in RNTX. Susquehanna International Group LLP bought a new stake in Rein Therapeutics in the third quarter valued at about $35,000. HRT Financial LP bought a new position in Rein Therapeutics during the fourth quarter worth about $38,000. Chicago Partners Investment Group LLC boosted its holdings in Rein Therapeutics by 32.2% during the first quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock valued at $53,000 after purchasing an additional 10,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new stake in Rein Therapeutics during the second quarter valued at approximately $68,000. Finally, Jane Street Group LLC bought a new stake in shares of Rein Therapeutics in the 4th quarter valued at approximately $72,000. 90.89% of the stock is currently owned by institutional investors and hedge funds.

Rein Therapeutics Stock Performance

NASDAQ:RNTX opened at $0.89 on Tuesday. The firm’s 50-day moving average is $0.84 and its 200-day moving average is $1.09. The company has a market cap of $76.70 million, a price-to-earnings ratio of -0.52 and a beta of 1.37. Rein Therapeutics has a 52-week low of $0.69 and a 52-week high of $2.18.

Rein Therapeutics (NASDAQ:RNTX) last released its earnings results on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.17. Equities analysts predict that Rein Therapeutics will post -0.47 EPS for the current year.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.